

PII: S0040-4020(97)00025-2

## Synthesis and Moulting Hormone Activity of 3-epi-2-Deoxy-20-hydroxyecdysone and Analogues

### Apichart Suksamrarn\* and Boon-ek Yingyongnarongkul

Department of Chemistry, Faculty of Science, Ramkhamhaeng University, Bangkok 10240, Thailand

**Abstract:** The minor ecdysteroid 3-*epi*-2-deoxy-20-hydroxyecdysone (3-*epi*-2-D-20-ECD) has been partially synthesized from 20-hydroxyecdysone. 2-D-5 $\alpha$ -20-ECD and the 3-dehydro analogues, 3-dehydro-2-D-20-ECD and 3-dehydro-2-D-5 $\alpha$ -20-ECD, have also been synthesized. Moulting hormone activity of these compounds has been studied using the *Musca* bioassay. © 1997 Elsevier Science Ltd. All rights reserved.

20-Hydroxyecdysone (20-ECD, 1) is a representative ecdysteroid with a 2,3-dihydroxyl function. Its 2deoxy analogues are minor ecdysteroids isolated from some plants and invertebrates.<sup>1</sup> Apart from 2-deoxy-20hydroxyecdysone (2-D-20-ECD, 2), 2-D-20-ECD 3-acetate (3), 2-D-20-ECD 22-acetate (4) and 2-D-20-ECD 22-benzoate (5) which have been mentioned previously,<sup>2</sup> 3-*epi*-2-D-20-ECD (6) is another member of this small group of ecdysteroids.<sup>1</sup> This compound has been isolated from the leech *Hinido medicinalis* as a metabolite of exogenous 2-deoxyecdysone (7)<sup>3</sup> and was a constituent of the plant *Tinospora capillipes*.<sup>4</sup> We wish to report partial synthesis of this rare ecdysteroid from the readily available ecdysteroid 1.<sup>5,6</sup> 2-D-5 $\alpha$ -20-ECD (8) and the 3-dehydro analogues, 3-dehydro-2-D-20-ECD (9) and 3-dehydro-2-D-5 $\alpha$ -20-ECD (10), have also been synthesized from 1. Moulting hormone activity of these ecdysteroids has been studied.







In order to synthesize the ecdysteroid 6, we initially planned to oxidize the ecdysteroid 2, synthesized previously by our group,<sup>2</sup> to the corresponding keto compound 9, which would then be selectively reduced to 6. However, a more concise route for the synthesis of 9 was devised and this was accomplished by a key step involving C3 dehydrogenation and C2 deoxygenation. From compound 9, the target ecdysteroid 6 has been synthesized. The keto compound 10 and the ecdysteroid analogue 8 have also been synthesized.

The C20 and C22 hydroxyl groups in 1 were protected as the acetonide 11 by the literature method.<sup>7</sup> Selective mesylation of 11 afforded the mesylate  $12^{2}$ , which upon treatment with aq. methanolic NaOH the



keto compound 13 was obtained. The structure of 13 has been established as followed. The presence of a new saturated keto group was evident from the IR absorption band at 1710 cm<sup>-1</sup>. The absence of carbinol protons at the C2 and C3 positions in the <sup>1</sup>H NMR spectrum was consistent with the structure 13. Placement of the saturated keto function at the C3 position of the A-ring, instead of the C2 position, was based on the mechanistic consideration as well as the absence of two sets of doublets, with a relatively large coupling constant, of two geminal protons at C1 position of the latter possible structure. The large upfield shift of H9 signal in CDCl<sub>3</sub> at  $\delta 2.78$  (as compared with  $\delta 3.01$  in 12) suggested the *trans*-A/B ring fusion<sup>8</sup> in 13. Furthermore, NOE experiment<sup>2</sup> also confirmed the  $\alpha$ -orientation of H5. Thus irradiation of the H5 signal at  $\delta 2.65$  gave rise to enhancement of H9 signal at  $\delta 2.78$ .



The results indicated that C5 epimerization has taken place at some stage in the reactions leading to the product 13. Epimerization at this position is known in ecdysteroid field.<sup>8,9</sup> Under the basic condition employed, H5 $\beta$  epimerized to H5 $\alpha$ . Two possible pathways leading to the product 13 could be proposed. The first possibility was the elimination of MsOH to give 14, followed by base-catalyzed epimerization of 14 to 13. The second possibility involved C5 epimerization of the *cis*-A/B mesylate 12 to the corresponding *trans*-A/B isomer 15, followed by elimination of MsOH to the ketone 13. We have re-investigated the reaction of 12 with aq. methanolic NaOH and, after careful TLC examination of the progress of the reaction, two almost completely overlapping spots were visualized, the less polar of which corresponded to compound 12. Just after the appearance of the more polar component, the product 13 which was the least polar component was detected. The new component was then isolated and identified as the mesylate 15. The <sup>1</sup>H NMR data was consistent with the structure 15, especially the relatively large upfield shift (0.34 ppm) of the H9 signal (as compared with the epimeric mesylate 12) which indicated that the A/B ring fusion was *trans*.<sup>8</sup> NOE enhancement of the H5 $\alpha$  signal at  $\delta 2.31$  was observed when the H9 signal at  $\delta 2.67$  was irradiated, thus confirming the  $\alpha$ -orientation of the H5. It was therefore most likely that the ketone 13 was produced through the intermediate mesylate 15.

Sodium borohydride reduction of 13 yielded an inseparable mixture of the alcohols 16 and 17 in a ratio of 5:1 (from <sup>1</sup>H NMR). The mixture was subjected to acetylation and the resulting acetylated mixture was chromatographed to afford individual compounds 18 and 19. The relatively upfield resonance of the <sup>1</sup>H NMR spectrum of H9 ( $\delta 2.68$ , CDCl<sub>3</sub>) of 18 suggested a *trans*-A/B ring system. A large peak-width at half-height ( $W_{1/2}$ , 23 Hz) of H3 signal at  $\delta 4.69$  indicated that the C3 hydroxyl group was in  $\beta$ -orientation<sup>10</sup> (i.e., H3 was in the axial configuration). Compound 19 was initially expected to be compound 20, the C3 epimer of 18. However, careful <sup>1</sup>H NMR analysis of this product has shown that it was compound 19, instead of 20. Thus a relatively downfield signal of H9 ( $\delta 3.15$ , CDCl<sub>3</sub>) suggested a *cis*-A/B ring fusion. Consequently, the C3 hydroxyl group should be in the  $\alpha$ -orientation since the  $W_{1/2}$  value of H3 at  $\delta 4.70$  was large<sup>10</sup> (23 Hz). In principle, the ecdysteroid 6 should be obtained from 19 by acetonide deprotection followed by deacetylation. However, it was obvious that the yield of 6 would be very low, since compound 19 was a minor component. We therefore would like to explore another alternative route.

It was evident that the major alcohol 16 resulted from the approach of the borohydride from the  $\alpha$ -face, the less hindered side of an ecdysteroid with a *trans*-A/B ring system. The minor alcohol 17 could arise from one of a number of possible pathways. The first possibility might involve epimerization of the initially formed alcohol 21 to the more stable C5 epimer 17, since the  $\alpha$ -orientation of the C3 hydroxyl group in 21 resulted in 1,3diaxial interaction of this group with the C1 and C5 axial hydrogens. The second possibility would involve C5 epimerization of the ketone 13 under the the reduction condition to the corresponding *cis*-A/B epimer 14, followed by borohydride reduction. In this case the reducing agent would approach the C3 keto function of 14 from the  $\beta$ -face, the less hindered side of an ecdysteroid with a *cis*-A/B ring junction.

In order to improve method of synthesis of 6 in higher yield, we then turn our interest to the synthesis of the ketone 14. To avoid epimerization at the C5 position of the mesylate 12 to the mesylate 15, or possibly the expected ketone 14 to the ketone 13, we have replaced NaHCO<sub>3</sub> for NaOH. This base, however, could also epimerize 12 to 15. Ecdysteroid without a  $2\beta$ -hydroxyl group was known to epimerize to the corresponding

15	CDCl <sub>3</sub>	4.93 (br s)	3.69 (m)		2.31 (dd, 12,	3.2)	) 5.90 (d, 2.7)	2.67 (m)	7, 2.20 (dd, 9.1,	(6.7	1, 3.63 (br d,	8.8)	0.77 (s)	0.98 (s)	1.13 (s)	1.20 (s)	1.21 (s)	1.30, 1.39	(each s)	ı	3.08 (s)
14	CDCl <sub>3</sub>		,		2.48*		5.88 (d,2.1	3.28 (m)	2.28 (dd, 9.	7.6)	3.66 (dd, 9.	2.4)	0.83 (s)	1.08 (s)	1.17 (s)	1.24 (s)	1.25 (s)	1.34, 1.42	(each s)	•	•
13	CDCl <sub>3</sub>		1		2.65 (dd,	12.5, 4.9)	5.94 (d, 2.7)	2.78 (m)	2.22 (m)		3.64 (dd, 9.5,	2.1)	0.81 (s)	1.04 (s)	1.15 (s)	1.21 (s)	1.22 (s)	1.31, 1.40	(each s)	ı	•
12	CDCl <sub>3</sub>	4.91 (m)	4.30 (br s)		2.52 (dd,	13.4, 3.9)	5.87 (d, 2.4)	3.01 (m)	2.23 (dd, 9.6,	7.5)	3.65 (dd, 9.4,	2.4)	0.80 (s)	1.02 (s)	1.16 (s)	1.24 (s)	1.25 (s)	1.33, 1.41	(each s)	1	3.09 (s)
10	C <sub>5</sub> D <sub>5</sub> N		ı		*		6.18 (d, 2.4)	3.09 (m)	#		3.88 (br d,	9.4)	1.21 (s)	1.03 (s)	1.59 (s)	1.38 (s)	1.38 (s)	I		ı	ı
6	C <sub>5</sub> D <sub>5</sub> N		ı		2.59 (dd,	11.4, 4.1)	6.19 (d, 2.1)	3.62 (m)	3.04 (t, 9.3)		3.88 (br d,	10)	1.22 (s)	1.04 (s)	1.60 (s)	1.36 (s)	1.36 (s)	ı		ı	ı
8	C <sub>5</sub> D <sub>5</sub> N		3.78 (br m,	$W_{1/2} = ca 21$ )	#		6.19 (d, 2.7)	3.02 (m)	$3.01^{#}$		3.89 (br d,	10)	1.21 (s)	0.91 (s)	1.59 (s)	1.38 (s)	1.38 (s)	ı		ı	ı
6	C <sub>5</sub> D <sub>5</sub> N		3.83 (br m,	$W_{1/2} = ca 25)$	2.29 (dd,	13.4, 3.6)	6.23 (d, 2.4)	3.70 (m)	3.02 (t, 9)		3.88 (br d,	10.1)	1.22 (s)	0.98 (s)	1.59 (s)	1.37 (s)	1.37 (s)	1		ı	I
	Н	2	3		S		2	6	17		22		18-Me	19 <b>-</b> Me	21-Me	26-Me	27-Me	)⊂(Me)2		Ac0	MsO

Table <sup>1</sup>H NMR Data of Ecdysteroids

<sup>≠</sup>Obscured signal. <sup>#</sup>Obscured by H9. <sup>\*</sup>Partially superimposed signal.

25	C <sub>5</sub> D <sub>5</sub> N		4.78 (br m)		¥		6.16 (d, 2.7)		2.99 (m)	3.00 (m) <sup>0</sup>		3.90 (d, 9.4)		1.19 (s)	0.86 (s)	1.58 (s)	1.38 (s)	1.38 (s)	ı		2.00 (s)
24	C <sub>5</sub> D <sub>5</sub> N		4.78 (br m)		#		6.22 (d, 2.1)		3.52 (m)	3.01 (t, 9.1)		3.88 (br d, 9.4)		1.20 (s)	0.91 (s)	1.59 (s)	1.36 (s)	1.36 (s)	1		1.91 (s)
23	CDCI <sub>3</sub>		5.05 (br s)		2.35 (dd, 12.5,	4.2)	5.83 (d, 2.4)		3.07 (m)	2.22 (dd, 9.6,	7.7)	3.64 (dd, 9.4,	2.1)	0.78 (s)	0.95 (s)	1.14 (s)	1.21 (s)	1.22 (s)	1.30, 1.39	(each s)	2.03 (s)
19	CDCl <sub>3</sub>		4.70 (br m,	$W_{1/2} = 23$ )	2.09 (dd, 13.3,	3.8)	5.84 (d, 2.4)		3.15 (m)	2.23 (dd, 9.7,	(6.7	3.64 (br d, 9.2)		0.78 (s)	0.91 (s)	1.14 (s)	1.22 (s)	1.23 (s)	1.31, 1.39	(each s)	1.98 (s)
18	CDCI <sub>3</sub>		4.69 (br m,	$W_{1/2} = 23)$	2.30 (dd, 12.2,	3.6)	5.88 (d, 2.7)		2.68 (m)	*		3.64 (dd, 9.2,	2.1)	0.78 (s)	0.85 (s)	1.14 (s)	1.21 (s)	1.22 (s)	1.31, 1.39	(each s)	2.01 (s)
17*	CDCl <sub>3</sub>		3.62 (br m)		#		5.86 (d,	<i>ca</i> 2)	3.17 (m)	ca 2.22 <sup>ª</sup>		3.66 (br d, 9.2)		0.80 (s)	0.92 (s)	1.16 (s)	1.23 (s)	1.24 (s)	1.33, 1.41	(each s)	,
16*	CDCI3		3.62 (br m)		2.27 (dd, 12.3,	3.7)	5.91 (d, 2.7)		2.69 (m)	ca 2.22 <sup>a</sup>		3.66 (br d, 9.2)		0.80 (s)	0.86 (s)	1.16 (s)	1.23 (s)	1.24 (s)	1.33, 1.41	(each s)	ı
	Н	2	ŝ		5		٢		6	17		22		18-Me	19-Me	21-Me	26-Me	27-Me	)⊂(Me)2		Ac0

Table <sup>1</sup>H NMR Data of Ecdysteroids (continued)

\*Assigned from a mixture of compounds 16 and 17.

<sup>≠</sup>Obscured signal.

 $\mathfrak{a},\mathfrak{b}_{Signals}$  with the same superscript denote partially superimposed signals.



*trans*-A/B fused epimer more readily than the one with such stabilizing group.<sup>10</sup> We then considered to use guanidine in place of the above inorganic bases. We have found that this organic base is a relatively milder base, but it was sufficiently strong for the hydrolysis of the ester group in an ecdysteroid molecule, even an ester which was difficult to hydrolyze.<sup>6</sup> In our experience, this base is suitable for working with ecdysteroids, since it did not cause epimerization at C5 position and did not catalyze autoxidation as some other bases did.<sup>11</sup> Moreover, use of base of this type with different basic strength can also be made by selection of various salts of this base (guanidine acetate, guanidine hydrochloride and guanidine nitrate, for example). In our case, guanidine hydrochloride-KHCO<sub>3</sub> (both 4:1 and 2:1 mol. ratio) still caused epimerization of the mesylate **12**, while guanidine itself had the problem concerning solubility in the solvent system used in the reaction. However, we found that guanidine acetate was a suitable base; the mesylate **12** has slowly been converted to the ketone **14** without detectable amount of the mesylate **15** as well as the epimeric ketone **13**. The *cis*-A/B nature of **14** was evident from a relatively lowfield resonance ( $\delta_3.28$ ) of the H9 signal, as compared with that of compound **13** ( $\delta_2.78$ ). The stereochemistry of the A/B ring junction was further confirmed by the following NOE experiments. Irradiation of the 19-Me signal at  $\delta_{1.08}$  caused enhancement in the signal of H5 at  $\delta_2.48$ . Enhancement of the 19-Me signal at  $\delta_{1.08}$  caused enhancement in the signal of H5 at  $\delta_2.48$ . Enhancement of the 19-Me signal was also observed when the H5 signal was subjected to irradiation.

Sodium borohydride reduction of the ketone 14 furnished a mixture of products showing only one homogeneous spot on TLC. The <sup>1</sup>H NMR spectrum revealed that it was in fact a mixture of one major product and minor product(s), the latter being present in quantity of less than *ca* 10%. The mixture was then subjected to acetylation and TLC of the crude products indicated one major and one minor acetates. <sup>1</sup>H NMR spectrum of the isolated major component was identical to 19, the minor acetylated product of the borohydride reduction of 13. The isolated minor component, on the other hand, turned out to be a mixture of two acetate derivatives. <sup>1</sup>H NMR spectrum of the first component of the minor acetate was identical to 18, the major acetylated product of the reduction product, from which the new acetylated product was obtained, could be the compound 21 or 22. However, <sup>1</sup>H NMR spectrum of the acetylated product suggested the compound to be 23 (the acetylated product of 22), not 20 (the acetylated product of 21), from the following observations. The relatively downfield signal of H9 at  $\delta 3.07$ , as compared with  $\delta 2.68$  of its C5 epimer 18, suggested the A/B ring junction to be *cis*. The broad singlet signal of H3 at  $\delta 5.05$  indicated the  $\beta$ -orientation of the C3 hydroxyl group. The ratio of the major acetate 19 and the minor acetates 18 and 23 was 10:1, while that of 18 and 23 was *ca* 10:7, the latter being estimated from <sup>1</sup>H NMR spectrum.

Sodium borohydride reduction of the *cis*-A/B fused ketone 14 thus provided a better method of synthesizing compound 17 (isolated as its acetate 19), which was then subjected to acetonide deprotection with 70% AcOH<sup>7</sup> to the acetate 24. Deacetylation of 24 was effected by treatment with guanidine acetate to yield 3-*epi*-2-D-20-ECD (6). The overall yield of 6 from the mesylate 12 was 21%. The spectroscopic (<sup>1</sup>H NMR, MS) data was consistent with the structure 6 and with the reported data of 6 synthesized previously by a different route.<sup>10</sup> In order to prove that deacetylation step of 24 to 6 with guanidine acetate did not cause C5

epimerization, NOE experiment of the product 6 has been performed. Thus irradiation of the 19-Me signal at  $\delta$  0.98 resulted in enhancement of the H5 signal at  $\delta$ 2.29.



In order to prepare ecdysteroid analogues for further studies, the compounds 13, 14 and 18 were subjected to deacetonation<sup>7</sup> and the compounds 10, 9 and 25 were respectively obtained. Compound 25 was deacetylated with guanidine acetate to yield compound 8. The spectroscopic data of these ecdysteroid analogues were consistent with their structures.



**Biological activity**. We have reported<sup>2</sup> that the moulting hormone activity of 2-D-20-ECD (2) was lower than that of 20-ECD (1) in the *Musca* bioassay. The activity of 2-D-20-ECD 3-acetate (3) was comparable to that of 2, but was higher than that of 2-D-20-ECD 22-acetate (4). 2-D-20-ECD 22-benzoate (5) was the least active ecdysteroid in the series. In the present work, we found that 3-epi-2-D-20-ECD (6) was much less active than 2, but it was nevertheless more active than 4. The reported<sup>10</sup> activity of the ecdysteroid 6 was 1/3 of that of 2 in the *Calliphora* assay; the activities of the two assays were therefore in the same direction.

Interestingly, the activity of 2-D-5 $\alpha$ -20-ECD (8), though relatively low, was comparable to that of 4. Since it was established that a *cis*-A/B ring junction is an essential feature for an ecdysteroid to exhibit moulting hormone activity,<sup>12</sup> the bioassay results suggested that the *in vivo* C5 epimerization of 8 to the corresponding *cis*-A/B fused ecdysteroid was possible.

Although the activity of 6 was also lower than that of 2 in our *Musca* assay, it was significantly higher than those of other  $3\alpha$ -hydroxy analogues.<sup>12</sup> One possible explanation for this rather unusually high activity was that the ecdysteroid 6 could be transformed to its C3 epimer, the ecdysteroid 2, possibly through the intermediate 9, 3-dehydro-2-D-20-ECD. We therefore determined the moulting hormone activity of 9 and it turned out that the activity of this compound was comparable to that of compound 4, thus suggesting that such *in vivo* transformation was possible. The activity of 3-dehydro-2-D-5 $\alpha$ -20-ECD (10) and 2-D-5 $\alpha$ -20-ECD (8), the C5 epimers of 9 and 2, respectively, have also been evaluated and, as expected, it was found that these compounds were less active than their C5 epimers. However, the positive bioassay results, though relatively less active, suggested that there might be mechanism(s) for these compounds to be converted to their C5 epimers. It worth to note that compound 10 was less active than 8 and possible explanation was that 10 required more step(s) in going to 2 (and then to 1) than that required in 8.

#### EXPERIMENTAL

IR spectra were recorded in KBr on a Jasco IR-700 spectrophotometer. <sup>1</sup>H NMR spectra were recorded on a Jeol JNM-A500 spectrometer. EI mass spectra were measured on a Hewlett Packard 5896 instrument operating at 70 eV. FAB mass spectra were measured on a Finnigan MAT 90 instrument. The microanalyses were performed by the Department of Chemistry, Faculty of Science, Mahidol University and the Scientific and Technological Research Equipment Centre, Chulalongkorn University. Column chromatography and TLC were carried out using Merck's silica gel 60 (>230 mesh) and precoated silica gel 60  $F_{254}$  plates, respectively. Spots on TLC were visualized under UV light and by spraying with anisaldehyde-H<sub>2</sub>SO<sub>4</sub> reagent followed by heating.

## Synthesis of 3-dehydro-2-D-5a-20-ECD 20,22-acetonide (13)

To a solution of the mesylate  $12^2$  (172 mg, 0.287 mmol) in MeOH (4 ml) was added 5% NaOH (5 ml, 6.250 mmol) and the reaction mixture stirred at ambient temperature for 50 min. The mixture was acidified with 5% AcOH and extracted with CHCl<sub>3</sub> (3x40 ml). The combined CHCl<sub>3</sub> extract was washed with water, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure to dryness. The crude mixture (126 mg) was purified by column chromatography using CHCl<sub>3</sub>-MeOH as eluting solvent, with increasing amount of the more polar component. Fractions eluted by CHCl<sub>3</sub>-MeOH (97.5:2.5) afforded **13** as gums (85 mg, 59%); IR: v<sub>max</sub> 3450, 2968, 1710, 1662, 1468, 1375, 1250, 1215, 1105, 1002, 745 cm<sup>-1</sup>; <sup>1</sup>H NMR data is given in Table; FABMS (-ve) : m/z 501.3217 [M-H]<sup>-</sup> C<sub>30</sub>H<sub>45</sub>O<sub>6</sub> requires 501.3216.

## Synthesis of 3-dehydro-2-D-5α-20-ECD 20,22-acetonide (13) and 5α-20-ECD 20,22-acetonide 2-mesylate (15)

The mesylate 12 (550 mg, 0.919 mmol) was reacted with 5% NaOH in the same manner as described in the above reaction, except that the reaction mixture was stirred for 30 min. The crude products were separated by column chromatography, using CHCl<sub>3</sub>-MeOH as eluting solvent. Fractions eluted by CHCl<sub>3</sub>-MeOH (97.5:2.5) afforded compound 13 (210 mg, 45%). The second combined fraction eluted by CHCl<sub>3</sub>-MeOH (95.5:4.5) gave the starting material 12 (95 mg). The last combined fraction, eluted by CHCl<sub>3</sub>-MeOH (95:5), was identified to be compound 15 and was obtained non-crystalline. (38 mg, 7%).

**15**: IR:  $v_{max}$  3438, 2970, 1667, 1458, 1374, 1340, 1253, 1216, 1172, 1093, 977, 919 cm<sup>-1</sup>; <sup>1</sup>H NMR data is given in Table; EIMS: m/z (% rel. intensity) 327 [M-C<sub>9</sub>H<sub>17</sub>O<sub>2</sub>-H<sub>2</sub>O-CH<sub>3</sub>SO<sub>3</sub>H]<sup>+</sup> (6), 309 (9), 283 (26), 265 (10), 231 (6), 213 (9), 201 (10), 195 (7), 183 (12), 158 (9), 143 (22), 140 (6), 125 (41), 122 (6); FABMS (-ve): m/z 597.3097 [M-H]<sup>-</sup>. C<sub>31</sub>H<sub>49</sub>O<sub>9</sub>S requires 597.3097.

#### Sodium borohydride reduction of 3-dehydro-2-D-5a-20-ECD 20,22-acetonide (13)

To a solution of the ketone **13** (43 mg, 0.085 mmol) in THF (1 ml) was added 2 ml (0.229 mmol) portion of the freshly prepared solution of NaBH<sub>4</sub> (13 mg in 3 ml absolute EtOH). After stirring for 5 min at ambient temperature, the reaction was stopped by addition of one drop of AcOH and water (60 ml) was then added. The resulting solution was extracted with CHCl<sub>3</sub> (3x15 ml); the combined CHCl<sub>3</sub> layer was washed with water, dried and evaporated. The crude mixture (53 mg) was subjected to column chromatography, using CHCl<sub>3</sub>-MeOH as eluting solvent. Fractions eluted by CHCl<sub>3</sub>-MeOH (97:3) gave an inseparable mixture, the <sup>1</sup>H NMR data of which (see Table) indicated a 5:1 mixture of 2-D-5 $\alpha$ -20-ECD 20,22-acetonide (16) and 3-*epi*-2-D-20-ECD 20,22-acetonide (17) (41 mg, 95%).

# Acetylation of a mixture 2-D-5 $\alpha$ -20-ECD 20,22-acetonide (16) and 3-*epi*-2-D-20-ECD 20,22-acetonide (17)

The mixture of compounds 16 and 17 (41 mg, 0.081 mmol) was dissolved in pyridine (2 ml), then Ac<sub>2</sub>O (0.5 ml, 5.294 mmol) was added. The reaction mixture was left to stir at ambient temperature for 2 h and worked up in the usual manner. The crude products were separated by column chromatography (CHCl<sub>3</sub>-MeOH from 99:1 to 98.5:1.5) to afford 3-*epi*-2-D-20-ECD 3-acetate 20,22-acetonide (19) (22 mg) and 2-D-5 $\alpha$ -20-ECD 3-acetate 20,22-acetonide (18) (19 mg).

**18**: Amorphous, mp 245-247 °C (from CHCl<sub>3</sub>-MeOH); IR:  $v_{max}$  3466, 2968, 1733, 1670, 1468, 1375, 1239, 1113, 1035, 1001, 927, 896, 870 cm<sup>-1</sup>; <sup>1</sup>H NMR data is given in Table; EIMS: m/z (% rel. intensity) 389

 $[M-C_9H_{17}O_2]^+$  (11), 371 (8), 329 (14), 327 (15), 311 (6), 267 (12), 201 (9), 183 (6), 158 (6), 143 (25), 125 (40); FABMS (+ve): m/z 547.3643  $[M+H]^+$ .  $C_{32}H_{51}O_7$  requires 547.3634.

**19**: Amorphous (from CHCl<sub>3</sub>-MeOH); IR:  $v_{max}$  3420, 2964, 1742, 1655, 1456, 1373, 1238, 1138, 1029 cm<sup>-1</sup>; <sup>1</sup>H NMR data is given in Table; EIMS: m/z (% rel. intensity) 389 [M-C<sub>9</sub>H<sub>17</sub>O<sub>2</sub>]<sup>+</sup> (7), 371 (16), 329 (41), 327 (15), 311 (20), 267 (26), 201 (11), 183 (10), 158 (8), 143 (38), 125 (63). Anal. Calcd. for C<sub>32</sub>H<sub>50</sub>O<sub>7</sub>: C, 70.32; H, 9.15. Found: C, 70.70; H, 8.72.

#### Synthesis of 3-dehydro-2-D-20-ECD 20,22-acetonide (14)

To a solution of the mesylate 12 (137 mg, 0.229 mmol) in MeOH (1 ml) was added 5% guanidine acetate (10 ml, 4.201 mmol) and the reaction mixture left to stir at 50 °C for 16 days. Water (100 ml) was then added and the mixture extracted with EtOAc (3x20 ml). The combined EtOAc layer was treated in the usual manner and the crude product (114 mg) was chromatographed using CHCl<sub>3</sub>-MeOH as eluting solvent. Fractions eluted by CHCl<sub>3</sub>-MeOH (97:3) afforded compound 14 as foams (96 mg, 84%); IR:  $v_{max}$  3438, 2966, 1711, 1662, 1453, 1373, 1251, 1216, 1172, 1103, 1001, 754 cm<sup>-1</sup>; <sup>1</sup>H NMR data is given in Table; EIMS: m/z (% rel. intensity) 474 [M-CO]<sup>‡</sup> (1), 456 (2), 438 (5), 396 (15), 314 (24), 298 (49), 271 (100), 91 (48); FABMS (-ve) : m/z 501.3219 [M-H]<sup>-</sup>. C<sub>30</sub>H<sub>45</sub>O<sub>6</sub> requires 501.3216.

#### Sodium borohydride reduction of 3-dehydro-2-D-20-ECD 20,22-acetonide (14)

Compound 14 (86 mg, 0.171 mmol) was subjected to sodium borohydride reduction in similar manner to that employed for compound 13, except that the reaction mixture was stirred at 5-10  $^{\circ}$ C in place of ambient temperature. The product was purified by column chromatography, using CHCl<sub>3</sub>-MeOH as eluting solvent, and fraction eluted by CHCl<sub>3</sub>-MeOH (97:3) gave a mixture of products (75 mg). <sup>1</sup>H NMR data indicated that the mixture consisted of the major product 17 and a small quantity of minor product(s). This mixture has been used in subsequent experiment.

#### Acetylation of a mixture of 3-epi-2-D-20-ECD 20,22-acetonide (17) and minor product(s)

The mixture of 17 and minor component(s) (29 mg) was subjected to acetylation in the same manner as described in case of the mixture of 16 and 17. The products were separated by column chromatography using CHCl<sub>3</sub>-MeOH as eluting solvent to give 3-*epi*-2-D-20-ECD 3-acetate 20,22-acetonide (19) (20 mg, 64%), eluted by CHCl<sub>3</sub>-MeOH (99.5:0.5). Fractions eluted by CHCl<sub>3</sub>-MeOH (99:1) afforded a *ca* 10:7 mixture of 2-D-20-ECD 3-acetate 20,22-acetonide (18) (3 mg, 10%).

## Acetonide deprotection of 3-epi-2-D-20-ECD 3-acetate 20,22-acetonide (19)

Compound **19** (16 mg, 0.029 mmol) was subjected to acetonide deprotection in the same manner as described for **18**. The products were purified in the usual fashion to afford 3-*epi*-2-D-20-ECD 3-acetate (**24**) as gums (10 mg, 67%); IR:  $v_{max}$  3420, 2964, 1742, 1655, 1456, 1373, 1307, 1238, 1176, 1138, 1103, 1081, 1029 cm<sup>-1</sup>; <sup>1</sup>H NMR data is given in Table; EIMS: m/z (% rel. intensity) 389 [M-C<sub>6</sub>H<sub>13</sub>O<sub>2</sub>]<sup>+</sup> (5), 371 (22), 329 (19), 311 (100), 293 (8), 267 (15), 161 (16), 143 (19), 125 (24), 117 (14), 107 (20), 99 (47), 81 (59); FABMS (-ve) : m/z 505.3164 [M-H]<sup>-</sup>. C<sub>29</sub>H<sub>45</sub>O<sub>7</sub> requires 505.3165.

#### Deacetylation of 3-epi-2-D-20-ECD 3-acetate (24)

To a solution of the acetate 24 (9 mg, 0.017 mmol) in MeOH (1 ml) was added 5% guanidine acetate (2 ml, 0.840 mmol) and the mixture stirred at 50 °C for 2 weeks. Water (40 ml) was then added and the mixture extracted with *n*-BuOH (3x20 ml). The combined organic layer was washed with water and evaporated by co-distillation with water under reduced pressure to afford 3-*epi*-2-D-20-ECD (6) (6 mg, 75%); IR:  $v_{max}$  3340, 2960, 1640, 1558, 1408, 1381, 1299, 1054, 963, 926, 874, 654 cm<sup>-1</sup>; <sup>1</sup>H NMR data is given in Table; FABMS (+ve): m/z 465.3217 [M+H]<sup>+</sup>. C<sub>27</sub>H<sub>45</sub>O<sub>6</sub> requires 465.3216.

## Acetonide deprotection of 3-dehydro-2-D-5a-20-ECD 20,22-acetonide (13)

The acetonide 13 (57 mg, 0.113 mmol) in 70% AcOH (2 ml) was stirred at ambient temperature for 4 days. Water (100 ml) was then added and the mixture extracted with *n*-BuOH (3x30 ml). The combined organic layer was washed with water and evaporated by co-distillation with water under reduced pressure. The crude mixture (40 mg) was subjected to column chromatography using CHCl<sub>3</sub>-MeOH as eluting solvent. Fractions eluted by CHCl<sub>3</sub>-MeOH (96:4) afforded the starting material 13 (5 mg) and fractions eluted by CHCl<sub>3</sub>-MeOH (95:5) gave 3-dehydro-2-D-5 $\alpha$ -20-ECD (10) as needles (from MeOH-CHCl<sub>3</sub>), mp 255-256 °C (31 mg, 60%)

based on unrecovered starting material); IR:  $\nu_{max}$  3416, 2960, 1711, 1657, 1461, 1377, 1184, 1152, 1125, 1067, 945, 919, 904, 865 cm<sup>-1</sup>; <sup>1</sup>H NMR data is given in Table; Anal. Calcd. for C<sub>27</sub>H<sub>42</sub>O<sub>6</sub>·1/2H<sub>2</sub>O: C, 68.78; H, 9.12. Found: C, 68.53; H, 9.14.

## Acetonide deprotection of 3-dehydro-2-D-20-ECD 20,22-acetonide (14)

The mesylate 14 (21 mg, 0.041 mmol) was subjected to acetonide deprotection in the same manner as described in case of preparation of 10 from 13. The product was purified by column chromatography to afford 3-dehydro-2-D-20-ECD (9) as powders (from MeOH-CHCl<sub>3</sub>), mp 225-226 °C (10 mg, 53%); IR:  $v_{max}$  3392, 2958, 1696, 1672, 1383, 1146, 919 cm<sup>-1</sup>; <sup>1</sup>H NMR data is given in Table; Anal. Calcd. for C<sub>27</sub>H<sub>42</sub>O<sub>6</sub>·1/2H<sub>2</sub>O: C, 68.78; H, 9.12. Found: C, 68.78; H, 8.80.

## Acetonide deprotection of 2-D-5α-20-ECD 3-acetate 20,22-acetonide (18)

Compound **18** (9 mg, 0.016 mmol) was treated with 70% AcOH (1 ml) and the mixture stirred at ambient temperature for 5 days. Water (30 ml) was then added and the mixture extracted with EtOAc (3x15 ml). The combined EtOAc extract was washed with water, dried and evaporated. The crude product (8 mg) was chromatographed using CHCl<sub>3</sub>-MeOH as eluting solvent. Fractions eluted by CHCl<sub>3</sub>-MeOH (97:3) gave 2-D- $5\alpha$ -20-ECD 3-acetate (**25**) as needles (from MeOH-CHCl<sub>3</sub>), mp 257-259 °C (6 mg, 75%); IR:  $v_{max}$  3420, 2958, 1735, 1712, 1656, 1464, 1381, 1237, 1135, 1029, 960, 902, 874, 835 cm<sup>-1</sup>; <sup>1</sup>H NMR data is given in Table; EIMS: m/z (% rel. intensity) 389 [M-C<sub>6</sub>H<sub>13</sub>O<sub>2</sub>]<sup>†</sup> (6), 371 (29), 329 (16), 327 (27), 311 (70), 293 (12), 285 (9), 267 (30), 161 (22), 143 (43), 125 (21), 117 (27), 107 (40), 99 (84), 81 (100); FABMS (-ve) : m/z 505.3162 [M-H]<sup>+</sup>. C<sub>29</sub>H<sub>45</sub>O<sub>7</sub> requires 505.3165.

#### Deacetylation of 2-D-5α-20-ECD 3-acetate (25)

The acetate **25** (5 mg, 0.009 mmol) was subjected to deacetylation in the same manner as described for compound **24** to give 2-D-5 $\alpha$ -20-ECD (8) (3 mg, 66%); IR:  $\nu_{max}$  3408, 2930, 1647, 1556, 1441, 1382, 1156, 1066, 900, 869, 848 cm<sup>-1</sup>; <sup>1</sup>H NMR data is given in Table; FABMS (+ve): m/z 465.3218 [M+H]<sup>+</sup>. C<sub>27</sub>H<sub>45</sub>O<sub>6</sub> requires 465.3216.

Biological activity testing. The Musca bioassay has been performed by the method referred to previously.<sup>5</sup>

Acknowledgements. This work was supported by the International Foundation for Science (IFS). We are grateful to Miss Wanwimon Thabdee for recording the NMR spectra, to Mr. Nitirat Chimnoi and Mr. Bruce Harrison for recording the FAB and El mass spectra.

#### REFERENCES

- 1. Lafont, R.; Wilson, I. D. The Ecdysone Handbook; The Chromatographic Society: Nottingham. 1992.
- 2. Suksamrarn, A.; Yingyongnarongkul, B. Tetrahedron 1996, 52, 12623-12630.
- 3. Garcia, M.; Garbi, J.; Girault, J.-P.; Hetru, C.; Lafont, R. Invert. Reprod. Devel. 1989, 15, 57-68.
- 4. Song, C.; Xu, R. Chin. Chem. Lett. 1991, 2, 13-14.
- 5. Suksamrarn, A.; Sommechai, C. Phytochemistry 1993, 32, 303-306.
- 6. Suksamrarn, A.; Sommechai, C.; Charulpong, P.; Chitkul, B. Phytochemitry 1995, 38, 473-476.
- 7. Suksamrarn, A.; Pattanaprateep, P. Tetrahedron 1995, 51, 10633-10650.
- 8. Girault, J.-P.; Blais, C.; Beynon, P.; Rolando, C.; Lafont, R. Arch. Insect Biochem. Physiol. 1989, 10, 199-213.
- 9. Greenwood, D. R.; Dinan, L. N.; Rees, H. H. Biochem. J. 1984, 217, 783-789.
- 10. Galbraith, M. N.; Horn, D. H. S.; Middleton, E. J.; Hackney, R. J. Aust. J. Chem. 1969, 22, 1059-1067.
- 11. Suksamrarn, A.; Ganpinyo, P.; Sommechai, C. Tetrahedron Lett. 1994, 35, 4445-4448.
- Bergamasco, R.; Horn, D. H. S. The Biological Activities of Ecdysteroids and Analogues. In Progress in Ecdysone Research; Hoffmann, J. A. Ed.; Elsevier/North-Holland Biomedical Press: Amsterdam, 1980; pp. 299-324.

(Received in UK 16 September 1996; revised 31 December 1996; accepted 9 January 1997)